Search
Sitagliptin
go.drugbank.com/drugs/DB01261ApprovedInvestigationalThe effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. … Sitagliptin was granted FDA approval on October 16, 2006[L6061].
Mixtures: Nb-sitagliptin-metformin, Nb-sitagliptin-metforminProducts: Nb-sitagliptinDesmopressin
go.drugbank.com/drugs/DB00035ApprovedInvestigationalIt is considered a first-line therapy for central diabetes insipidus but is ineffective in patients with nephrogenic diabetes insipidus, where the kidneys are non-responsive to the hormone [A275458, L56105 … Additionally, it serves as a critical hematologic agent for the management of mild hemophilia A and von Willebrand disease (Type I) by transiently increasing levels of clotting factors [A31662, A275458
Products: Nu-desmopressin SprayTicagrelor
go.drugbank.com/drugs/DB08816ApprovedInvestigational[A2903] Unlike [clopidogrel], ticagrelor is not a prodrug.[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. … Ticagrelor was granted EMA approval on 3 December 2010.[L14207] Ticagrelor was granted FDA approval on 20 July 2011.[L14201]
Products: NaPituitary Adenoma
go.drugbank.com/conditions/DBCOND0042383Drugs: CabergolineSynonyms: Pituitary adenoma, no ICD-O subtype, Pituitary adenoma, no International Classification of Diseases for Oncology subtypeLeukemias
go.drugbank.com/conditions/DBCOND0035632Drugs: Allopurinol · Betamethasone · Bupivacaine · Hydrocortisone · Hydrocortisone succinate · Methylprednisolone +4 moreSynonyms: Leukemia, no ICD-O subtype, Leukaemia, no ICD-O subtypeAlendronic acid
go.drugbank.com/drugs/DB00630ApprovedInvestigationalIt functions by preventing resorption of bone[FDA Label][A959].
Mixtures: ALENDRON-HEXAL 4 WO CAL D, ALENDRON-HEXAL 12 WO CAL DProducts: Nb-alendronate-FCPidolic acid
go.drugbank.com/drugs/DB03088ApprovedInvestigationalPidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics … Although pidolic acid is included in some over-the-counter, non-prescription dietary supplements for the proposed purpose of facilitating cognitive or memory enhancement, most available research suggest
Ergoloid mesylate
go.drugbank.com/drugs/DB01049Approved[A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued. … [L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: co-dergocrine mesilate, co-dergocrine mesylateChronic Myelogenous Leukemia (CML)
go.drugbank.com/conditions/DBCOND0040386Synonyms: Chronic myelogenous leukemia, no ICD-O subtype, Chronic myelogenous leukemia, no ICD-O subtype (morphologic abnormality)